Open-Label Extension Study of Trofinetide for Rett Syndrome

NCT04776746 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
77
Enrollment
INDUSTRY
Sponsor class

Stopped As a result of marketing approval of trofinetide on 10 March 2023, the study was terminated by the Sponsor with the intent of switching patients to commercially available product.

Conditions

Interventions

Sponsor

ACADIA Pharmaceuticals Inc.